Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups

US11123439B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Hans-Georg Lerchen · Leverkusen, DE
• Anne-Sophie REBSTOCK · Écully, FR
• Yolanda Cancho Grande · Leverkusen, DE
• Leo MARX · Wuppertal, DE
• Beatrix Stelte-Ludwig · Wülfrath, DE
• Carsten TERJUNG · Bochum, DE
• Christoph MAHLERT · Wuppertal, DE
• Simone Greven · Dormagen, DE
• Anette SOMMER · Berlin, DE
• Sandra BERNDT · Hohen Neuendorf, DE

Key dates

• Filing date: Jun 20, 2016
• Grant date: Sep 21, 2021
• Expiry date: Oct 25, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.